"Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community
Paul Mackin, PhD, MRCPsych, David Bishop, MRes, Helen Watkinson, BSc, Peter Gallagher, MPhil and I. Nicol Ferrier, MD, FRCPsych
School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon Tyne, UK
Correspondence: Dr Paul Mackin, School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon Tyne, Leazes Wing (Psychiatry), Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK. Email: paul.mackin@ncl.ac.uk
Declaration of Interest P.M., I.N.F. and P.G. have received honoraria for educational meetings from pharmaceutical companies. Funding detailed in Acknowledgements.
Background Prevalence of physical comorbidity in severe mentalillness is a significant public health concern, but comparative data in people with diagnoses other than schizophrenia are sparse.
Aims To investigate the prevalence of metabolic disease and cardiovascular risk in people with severe mental illness treated with antipsychotics in the community.
Methods Case-control study of 90 people treated with antipsychotics in the community and 92 age- and gender-matched controls. The prevalence of metabolic syndrome and 10-year cardiovascular risk were calculated.
Results People on antipsychotics had a significantly worse metabolic profile than controls (F=6.583, d.f.=15,161, P<0.0001). Moreover, metabolic syndrome was more prevalent (OR=3.68, 95% CI 1.71-7.93, P=0.001), as was cardiovascular risk across a number of outcomes. These results are consistent across diagnostic groups.
Conclusions People with severe mental illness treated with antipsychotics have excess metabolic dysfunction and heightened risk for cardiovascular disease.
Related articles in BJP:
- Highlights of this issue
- Sukhwinder S. Shergill
BJP 2007 191: 2. [Full Text]
eLetters:
Read all eLetters
- metabolic syndrome in patients with learning disabilities
- Padmaja Sivakumar
- BJP Online, 5 Jul 2007 [Full text] "